The U.S. healthcare landscape in 2025 is witnessing an intriguing intersection: the surge of weight-loss medications alongside renewed debates over ivermectin covid. With GLP-1 drugs such as semaglutide expanding rapidly, Americans are evaluating options for obesity management while reconsidering alternative treatments like Ivermectin. Public discussions increasingly focus on...